Teleflexの空売り状況は、投資家がTeleflexの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Teleflex (NYSE:TFX) 株価情報, 空売り情報

Teleflex

Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.

Teleflex Inc

<p>In the current session, <strong>Teleflex Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>)</strong> is trading at $180.00, after a <strong>0.08%</strong> decrease. Over the past month, the stock decreased by <strong>6.59%</strong>, and in the past year, by <strong>28.07%</strong>. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2024/1735308911_0.png" alt="Past Year Chart" /></p>

<h3>How Does Teleflex P/E Compare to Other Companies?</h3>
<p>The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. </p>
<p>Compared to the aggregate P/E ratio of the <strong>67.67</strong> in the Health Care Equipment &amp; Supplies industry, Teleflex Inc. has a lower P/E ratio of <strong>35.74</strong>. Shareholders might be inclined to think that  the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2024/1735308911_1.png" alt="Guage" /></p>

<p>In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes. </p>


News

Intraday Update

Markets

P/E Ratio Insights for Teleflex

<p>Truist Securities  analyst Richard Newitter   maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Hold and lowers the price target from $227 to $200.</p>


Price Target

Analyst Ratings

Truist Securities Maintains Hold on Teleflex, Lowers Price Target to $200

<p>In the last three months, 5 analysts have published ratings on Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $250.4, a high estimate of $275.00, and a low estimate of $227.00. Experiencing a 4.57% decline, the current average is now lower than the previous average price target of $262.40. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734375625_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A clear picture of Teleflex's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$227.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$250.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$245.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$255.00</td>
<td>$247.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$275.00</td>
<td>$260.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Teleflex. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Teleflex compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Teleflex's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Teleflex's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TFX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Teleflex analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Teleflex</h2>
<p>Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.</p>
<h3>Teleflex: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Teleflex displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>2.41%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Teleflex's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>14.52%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Teleflex's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>2.46%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Teleflex's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>1.49%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Teleflex's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.42</strong>.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Where Teleflex Stands With Analysts

<p>Needham  analyst Mike Matson   reiterates Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) from Hold to Hold.</p>


Reiteration

Needham Reiterates Hold on Teleflexto Hold

Teleflex Is Said To Offer €500M To €1B For Biotronik Unit

<p>Truist Securities  analyst Richard Newitter   reiterates Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Hold and lowers the price target from $255 to $227.</p>


Truist Securities Reiterates Hold on Teleflex, Lowers Price Target to $227

<p>Mizuho  analyst Anthony Petrone   maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Neutral and lowers the price target from $275 to $250.</p>


Mizuho Maintains Neutral on Teleflex, Lowers Price Target to $250

<p>RBC Capital  analyst Shagun Singh   maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Outperform and lowers the price target from $275 to $245.</p>


RBC Capital Maintains Outperform on Teleflex, Lowers Price Target to $245

<p>Needham  analyst Mike Matson   reiterates Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Hold.</p>


Needham Reiterates Hold on Teleflex

WIIM

Teleflex shares are trading lower after the company reported mixed Q3 financial results and cut FY24 revenue growth guidance.

Guidance

Teleflex Lowers FY24 GAAP Revenue Growth Guidance Range From 3.40% - 4.40% To 2.90% - 3.40%, Revises Adjusted EPS From Continuing Operations Guidance From  $13.80 - $14.20 To $13.90 - $14.20, Est $13.97

<p>Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) reported quarterly earnings of $3.49 per share which beat the analyst consensus estimate of $3.39 by 2.95 percent. This is a 4.12 percent decrease over earnings of $3.64 per share from the same period last year.  The company reported quarterly sales of $764.38 million which missed the analyst consensus estimate of $769.60 million by 0.68 percent.  This is a 2.41 percent increase over sales of $746.39 million the same period last year.</p>


Earnings

Earnings Beats

Earnings Misses

Teleflex Q3 2024 Adj EPS $3.49 Beats $3.39 Estimate, Sales $764.38M Miss $769.60M Estimate

<p>Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) is gearing up to announce its quarterly earnings on Thursday, 2024-10-31. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Teleflex will report an <strong>earnings per share</strong> (EPS) of $3.39.</p>
<p>Investors in Teleflex are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS beat by $0.09 in the last quarter, leading to a 0.5% increase in the share price on the following day.</p>
<p>Here's a look at Teleflex's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>3.33</td>
<td>3.07</td>
<td>3.26</td>
<td>3.27</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>3.42</td>
<td>3.21</td>
<td>3.38</td>
<td>3.64</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>2.0%</td>
<td>0.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730322284_0.png" alt="eps graph" /></p>
<h3>Analyst Opinions on Teleflex</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Teleflex.</p>
<p>The consensus rating for Teleflex is Outperform, based on 6 analyst ratings. With an average one-year price target of $264.5, there's a potential 11.87% upside.</p>
<h3>Understanding Analyst Ratings Among Peers</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of Globus Medical, Penumbra and Glaukos, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>As per analysts' assessments, Globus Medical is favoring an Outperform trajectory, with an average 1-year price target of $80.43, suggesting a potential 65.98% downside.</li>
<li>The prevailing sentiment among analysts is an Buy trajectory for Penumbra, with an average 1-year price target of $230.67, implying a potential 2.44% downside.</li>
<li>The prevailing sentiment among analysts is an Buy trajectory for Glaukos, with an average 1-year price target of $141.86, implying a potential 40.0% downside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Globus Medical, Penumbra and Glaukos, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Teleflex</td>
<td>Outperform</td>
<td>0.87%</td>
<td>$416.46M</td>
<td>1.77%</td>
</tr>
<tr>
<td>Globus Medical</td>
<td>Outperform</td>
<td>115.93%</td>
<td>$369.65M</td>
<td>0.80%</td>
</tr>
<tr>
<td>Penumbra</td>
<td>Buy</td>
<td>14.49%</td>
<td>$162.83M</td>
<td>-5.09%</td>
</tr>
<tr>
<td>Glaukos</td>
<td>Buy</td>
<td>19.02%</td>
<td>$73.14M</td>
<td>-9.06%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Teleflex ranks at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.</p>
<h3>Discovering Teleflex: A Closer Look</h3>
<p>Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.</p>
<h3>Teleflex's Financial Performance</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Teleflex showcased positive performance, achieving a revenue growth rate of <strong>0.87%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Teleflex's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>10.68%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Teleflex's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>1.77%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Teleflex's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.07%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.4</strong>, Teleflex adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/TFX/earnings"><strong>To track all earnings releases for Teleflex visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Look Ahead: Teleflex's Earnings Forecast

Health Care

General

Teleflex Has Enrolled The First Patient In PPRT Trial To Evaluate Barrigel Rectal Spacer, A Sculptable Hyaluronic Acid Rectal Spacer Designed To Significantly Reduce Radiation That Reaches The Rectum During Prostate Radiation Therapy

Teleflex Announced The Launch Of Two New Devices In Canada Designed To Enhance Picc Insertion Procedures And Reduce The Chance Of Complications

<p><strong>Teleflex's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) short percent of float has risen 32.29% since its last report. The company recently reported that it has <strong>754 thousand shares sold short</strong>, which is 2.54% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.25 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Teleflex Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729614612_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Teleflex has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Teleflex's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Teleflex's peer group average for short interest as a percentage of float is 4.24%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Trading Ideas

Peering Into Teleflex's Recent Short Interest

<ul>
<li>Barrigel rectal spacer provides high quality rectal spacing, enabling low dose to the rectum during prostate cancer radiation therapy, with an excellent toxicity and safety profile; and low incidence (0.32-1%) of rectal wall infiltration (RWI), which can be safely reversed using hyaluronidase.</li>
<li>Data demonstrate safety and efficacy of Barrigel rectal spacer in stereotactic body radiation therapy (SBRT) for patients undergoing repeat therapy.</li>
</ul>


Teleflex Announced The Presentation Of Data Supporting The Safety And Efficacy Of Barrigel Rectal Spacer, To Reduce Radiation That Reaches The Rectum During Prostate Cancer Radiation Therapy

<p>Ratings for Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $264.5, along with a high estimate of $290.00 and a low estimate of $247.00. Surpassing the previous average price target of $252.83, the current average has increased by 4.62%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1728921650_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The standing of Teleflex among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$255.00</td>
<td>$247.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$275.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$247.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>George Sellers</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$290.00</td>
<td>$275.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Teleflex. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Teleflex compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Teleflex's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Teleflex's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TFX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Teleflex analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Teleflex</h2>
<p>Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.</p>
<h3>Teleflex: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Teleflex showcased positive performance, achieving a revenue growth rate of <strong>0.87%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Teleflex's net margin excels beyond industry benchmarks, reaching <strong>10.68%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Teleflex's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>1.77%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Teleflex's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>1.07%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.4</strong>, Teleflex adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


<p>Truist Securities  analyst Richard Newitter   maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Hold and raises the price target from $247 to $255.</p>


Truist Securities Maintains Hold on Teleflex, Raises Price Target to $255

<p>RBC Capital  analyst Shagun Singh   maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Outperform and raises the price target from $260 to $275.</p>


RBC Capital Maintains Outperform on Teleflex, Raises Price Target to $275

Morgan Stanley lists hedge funds' largest Q3 ownership increases in Russell 1000 stocks

Janus Henderson Contrarian Fund Q3 2024 Commentary

Janus Henderson Enterprise Fund Q3 2024 Commentary

Janus Henderson Mid Cap Growth Managed Account Q3 2024 Commentary

Janus Henderson Opportunistic Alpha Managed Account Q3 2024 Commentary

Teleflex (TFX) is in discussions to acquire Biotronik SE & Co.'s vascular intervention unit, offering to buy the German medical technology firm's b...

Teleflex in talks to buy Biotronik stent unit, Bloomberg says

Teleflex Incorporated: Compelling Only On One Metric

Needham analyst Michael Matson maintained a Hold rating on Teleflex (TFX – Research Report) today. The company's shares closed last Friday at $180....

Needham Reaffirms Their Hold Rating on Teleflex (TFX)

Worst performing stocks for tax loss selling – Wolfe

Truist lowered the firm's price target on Teleflex (TFX) to $200 from $227 and keeps a Hold rating on the shares as part of a broader research note...

Teleflex price target lowered to $200 from $227 at Truist

ACHC

ACLS

AGCO

ALGM

AMKR

AMZN

APLS

ASTS

ASTSW

ATKR

AZEK

BIIB

BILL

BMRN

BRBR

CAVA

CHRW

CIVI

CLVT

CNSWF

CNXC

COLD

CSTM

CTLT

DINO

DLTR

DXCM

ENPH

FIVN

FLEX

FLNC

FWONA

FWONB

FWONK

GDDY

GOOG

GOOGL

GTLS

ICUI

IFCZF

INTC

IONS

IPGP

JAAA

JBBB

JMBS

JSMD

JSML

LITE

LPLA

LRCX

MCHP

MDGL

MRNA

MRVL

MTCH

NEOG

NXPI

OPCH

ORCL

PTEN

QDEL

QGEN

QRVO

REGN

REXR

RKLIF

RVTY

SCHW

SEDG

SGRY

SOLV

SSNC

STNE

SWKS

SYNA

VNLA

WING

WOLF

XRAY

Press Releases

Teleflex™ Chooses o9's AI-Powered Platform for End-to-End Integrated Business Planning and Supply Chain Management

Teleflex's Barrigel Rectal Spacer to Be Featured in Three Presentations at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting

Teleflex Announces Third Quarter 2024 Earnings Conference Call Information

New Data Presented at ASTRO 2024 Further Demonstrate the Safety and Efficacy of Barrigel™ Rectal Spacer, the First and Only Sculptable Hyaluronic Acid Rectal Spacer, in Patients Undergoing Radiation Therapy for Prostate Cancer(1-3)

Teleflex launches next-generation Arrow™ VPS Rhythm™ DLX Device and NaviCurve™ Stylet in Canada

First Patient Enrolled in Teleflex's Barrigel™ Rectal Spacer Trial for Post Radical Prostatectomy Radiation Therapy (PPRT)

Comments

Teleflex

空売り

Teleflex (NYSE:TFX) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル